Literature DB >> 34339386

Impact of Recent SARS-CoV-2 Infection on the Course and Severity of Dengue in Children: A Prospective Observational Study from North India.

Namita Ravikumar1, Manjinder Singh Randhawa2, Karthi Nallasamy2, Suresh Kumar Angurana2, Mahendra Kumar3, Gursimran Kaur Mohi4, Radha Kanta Ratho4, Muralidharan Jayashree2.   

Abstract

In 2020, a considerable overlap occurred between the COVID-19 pandemic and seasonal dengue transmission in India. This study aimed to evaluate the effects of acute or recent infection with SARS-CoV-2 on the course and outcomes of dengue fever in children. We prospectively enrolled 44 children with a clinical and laboratory diagnosis of dengue fever. Assessment of acute and recent SARS-CoV-2 infection was done using reverse transcription-polymerase chain reaction and IgG antibody through ELISA. Children were grouped based on evidence of SARS-CoV-2 exposure and clinical severity, and outcomes were compared. The median age of the study cohort was 96 months (interquartile range [IQR]: 69-129 months). Fever (98%), vomiting (78%), abdominal pain (68%), hepatomegaly (68%), and edema (32%) were the common features. About two-thirds (N = 30) had severe dengue; 20 (45%) had dengue shock. Liver dysfunction (58%) and acute kidney injury (25%) were other major organ dysfunctions. Nineteen (43%) children stayed in the pediatric intensive care unit for a median duration of 5 days (IQR: 2-11 days). None had acute SARS-CoV2 infection; however, IgG against SARS-CoV-2 was detected in 15 (34%) cases. Children with recent exposure to SARS-CoV-2 showed a trend toward a lower incidence of acute kidney injury, fewer organ dysfunctions, and a lower frequency of invasive ventilation. Four children (9%) died; none of the deaths were in the SARS-CoV-2-exposed group. The present study exposes preliminary evidence that dengue fever might follow a less severe course in children with recent exposure to SARS-CoV-2 infection. However, it is pertinent to understand the antigenic similarity and cross-protective antibody response between the two viruses and their clinical relevance.

Entities:  

Year:  2021        PMID: 34339386     DOI: 10.4269/ajtmh.21-0586

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  3 in total

1.  Comparison of Multisystem Inflammatory Syndrome (MIS-C) and Dengue in Hospitalized Children.

Authors:  Manjinder Singh Randhawa; Suresh Kumar Angurana; Karthi Nallasamy; Mahendra Kumar; Namita Ravikumar; Puspraj Awasthi; Arnab Ghosh; R K Ratho; Ranjana W Minz; Rohit Manoj Kumar; Arun Bansal; Muralidharan Jayashree
Journal:  Indian J Pediatr       Date:  2022-05-05       Impact factor: 5.319

2.  Antibodies against the SARS-CoV-2 S1-RBD cross-react with dengue virus and hinder dengue pathogenesis.

Authors:  Yi-Ling Cheng; Chiao-Hsuan Chao; Yen-Chung Lai; Kun-Han Hsieh; Jen-Ren Wang; Shu-Wen Wan; Hong-Jyun Huang; Yung-Chun Chuang; Woei-Jer Chuang; Trai-Ming Yeh
Journal:  Front Immunol       Date:  2022-08-15       Impact factor: 8.786

3.  COVID-19 serum can be cross-reactive and neutralizing against the dengue virus, as observed by the dengue virus neutralization test.

Authors:  Himadri Nath; Abinash Mallick; Subrata Roy; Tathagata Kayal; Sumit Ranjan; Susanta Sengupta; Soumi Sukla; Subhajit Biswas
Journal:  Int J Infect Dis       Date:  2022-07-08       Impact factor: 12.074

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.